Key facts
- Navinci’s last known valuation is $23.3M (Jul 2022).
- It has raised $18.2M; the latest was Later Stage VC ($6.1M) in Jun 2025.
- Notable investors include Meltwind Advisory, Beijer Ventures, Landegren Gene Technology AB, Nxt2b, Segulah Medical Acceleration — 7 tracked in total.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Navinci
- ·The full record, as it builds
Funding rounds
No funding rounds for Navinci are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Navinci
Operator of a biotechnology company intended to develop technology for the detection and quantification of proteins, their interactions, and modifications. The company offers an in-house immunostaining service that combines antibody-based proteomic technologies with fluorescence readout to improve human health, enabling scientists to study proteins and their interactions and analysis in cells and tissues to understand human biology and develop drugs.
- Sector
- Healthcare
- HQ
- Uppsala, Sweden
- Founded
- 2004
- Employees
- 29
- Website
- navinci.se/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Navinci doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Navinci shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Navinci in its N-PORT filings yet. We sweep new filings monthly.